Performance assessment on manufacturing of unfired bricks using industrial wastes

This paper presents eco-friendly unburnt bricks made up of fly ash, waste plastic powder, waste glass powder, lime, gypsum and crusher sand as alternatives to conventional burnt clay bricks for sustainable development. The research focuses on the maximum utilization of industrial waste in eco-friendly unburnt brick production. Materials are characterized according to their chemical and geotechnical properties. In this research, we use a milled waste glass powder of size less than 600μm and plastic powder obtained from plastic waste of size less than 600μm are added along with crushed sand, gypsum, lime and fly ash with various mix proportions concerning FaL-G mix concept. All the proportions were taken on a weight basis. Compressive strength, water absorption, and efflorescence are the key parameters chosen for comparing the innovative brick with conventional fly ash brick. There are five different mixes (Type A, B, C, D & E) are made in this research. The plastic and glass powders are replaced by crusher sand at the increased rate of 2% in every mix whereas 2%,4%,6%,8%, and 10%. It was found that the type B bricks have 17.63% strength was increased when compared to base mix. From the test results, type B bricks have enhanced mechanical performance when compared to all other mixes

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

SMART PATROL ALLOCATION SYSTEM

The increasing crime rate in smart cities demands a “smart” way to handle the situation. The objective of this article is to propose a methodology to strategically place a minimum number of police patrollers at road junctions such that positioning of the patrollers will achieve maximum visibility of the given geographical command efficiently. The notion of dominating set is applied to find the strategical locations at which the patrollers have to be placed. Also to allocate given patrollers optimally on these strategical locations we employ a priority based allocation to allocate them on the nodes that demand a higher importance. To experiment, the proposed model is tested for a place in Chennai, Tamilnadu, India. The results show that by only placing the patrollers on 1/3 of the total number of junctions, spatial visibility of all the junctions in the geographic command can be achieved. If provided with the number of patrollers available to be allocated, then the algorithm can optimally allocate the given patroller

Not Available

Not AvailableStudy was carried out to assess supplemental effects of dietary reduced ubiquinol (rCoQ10) on lipid profile and serum antioxidant activity in broiler chicks fed diets with three energy levels. 270 broiler chicks divided into nine groups (3 energy levels x 3 levels of rCoQ10) with three replicates. Birds were fed with basal energy (BE), low energy (BE-100 (kcal)) and high energy (BE+100 (kcal.kg-1) feed) and rCoQ10 at 0, 20 and 40ppm. Broiler chicks were distributed in completely randomized design and reared for 42d and at end of study, serum and muscle samples were collected for antioxidant activities, lipid contents. The activity of superoxide dismutase, glutathione peroxidase, reduced glutathione, vitamin E were increased and serum malonaldehyde, total, LDL-cholesterol as well as muscle cholesterol were reduced by intake of rCoQ10. The consumption of rCoQ10 improved muscle oxidative stability than the control. Ubiquinol at 20ppm favourably altered lipid profile with reduced lipid peroxidation and improved serum antioxidants activities.Not Availabl

Not Available

Not AvailableNot AvailableNot Availabl

Not Available

Not AvailableNot AvailableNot Availabl

Not Available

Not AvailableNot AvailableNot Availabl